Stock Scorer

ARS Pharmaceuticals, Inc. (SPRY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 30M 60M 90M Q1 '22: 663K Q2 '22: 464K Q3 '22: 189K Q4 '22: 0 Q1 '23: 20K Q2 '23: 10K Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 500K Q3 '24: 2.1M Q4 '24: 86.6M Q1 '25: 8M Q2 '25: 15.7M Q3 '25: 32.5M Q4 '25: 28.1M Q1 '26: 22.7M Q2 '26: 33.7M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -22.7M Q4 '21: 46.6M Q1 '22: -7.1M Q2 '22: -6.3M Q3 '22: -6.6M Q4 '22: -15.4M Q1 '23: -18.7M Q2 '23: -20.6M Q3 '23: -18M Q4 '23: -10.2M Q1 '24: -13.2M Q2 '24: -15.3M Q3 '24: -21.7M Q4 '24: 47.2M Q1 '25: -37.2M Q2 '25: -47.6M Q3 '25: -53.2M Q4 '25: -41.5M Q1 '26: -60.1M Q2 '26: -61.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -22.7M Q4 '21: 45.8M Q1 '22: -7.2M Q2 '22: -6.4M Q3 '22: -6.6M Q4 '22: -14.4M Q1 '23: -15M Q2 '23: -17.4M Q3 '23: -14.9M Q4 '23: -7.2M Q1 '24: -10.3M Q2 '24: -12.5M Q3 '24: -19.1M Q4 '24: 49.9M Q1 '25: -33.9M Q2 '25: -44.9M Q3 '25: -51.2M Q4 '25: -41.3M Q1 '26: -60.6M Q2 '26: -62.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q2 '21: -14.1M Q3 '21: -19.1M Q4 '21: 27.9M Q1 '22: -6.9M Q2 '22: -7M Q3 '22: -5.7M Q4 '22: -20.5M Q1 '23: -12.4M Q2 '23: -16.7M Q3 '23: -12.8M Q4 '23: -17.4M Q1 '24: -6.7M Q2 '24: -7.3M Q3 '24: -14.5M Q1 '25: -40.7M Q2 '25: -39.6M Q3 '25: -47M Q4 '25: -43.5M Q1 '26: -44.9M Q2 '26: -60.9M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q4 '20: -11.3M Q1 '21: -12.2M Q2 '21: -14.8M Q3 '21: -19.2M Q1 '22: -6.9M Q2 '22: -7M Q3 '22: -5.7M Q4 '22: -20.6M Q1 '23: -12.6M Q2 '23: -16.7M Q3 '23: -12.8M Q1 '24: -6.8M Q2 '24: -7.3M Q3 '24: -14.6M Q1 '25: -40.8M Q2 '25: -39.6M Q3 '25: -47.2M Q4 '25: -43.5M Q1 '26: -44.9M Q2 '26: -60.9M Q1 '21 Q1 '22 Q4 '22 Q3 '23 Q3 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q3 '21: 35M Q1 '22: 30.4M Q2 '22: 30.6M Q3 '22: 30.8M Q1 '23: 94.2M Q2 '23: 94.9M Q3 '23: 95.6M Q1 '24: 96.5M Q2 '24: 96.8M Q3 '24: 97M Q1 '25: 98.1M Q2 '25: 98.4M Q3 '25: 98.8M Q1 '26: 99.3M Q2 '26: 99.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 0.00 6.00 12.00 18.00 Q3 '21: 16.29 Q4 '21: -2.56 Q1 '22: -2.26 Q2 '22: -1.77 Q3 '22: -1.33 Q4 '22: -0.87 Q1 '23: -0.79 Q2 '23: -0.76 Q3 '23: -0.71 Q4 '23: -0.57 Q1 '24: -0.52 Q2 '24: -0.47 Q3 '24: -0.51 Q4 '24: 0.08 Q1 '25: -0.16 Q2 '25: -0.49 Q3 '25: -0.81 Q4 '25: -1.75 Q1 '26: -2.01 Q2 '26: -2.18 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for SPRY: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.